Please Share:: 
India Equity Research Reports, IPO and Stock News
Visit http://indiaer.blogspot.com/ for complete details �� ��
Sun Pharma gets USFDA approval for generic Razadyne ER
Sun Pharma announced that its subsidiary has received USFDA approval for its ANDA to
market the generic version of Razadyne ER, (galantamine hydrobromide), extended-release
capsules. These extended-release capsules, 8 mg (base), 16 mg (base) and 24 mg (base),
are indicated in the treatment of mild to moderate dementia of the Alzheimer’s type.
Razadyne-ER has annual sales of approximately US $50mn in the US. Razadyne is a
registered trademark of Ortho-McNeil Janssen Pharmaceuticals, Inc.
Considering the market size of the product, the upsides from the same would be limited and
thereby we maintain our estimates and have a Neutral rating on the stock
India Equity Research Reports, IPO and Stock News
Visit http://indiaer.blogspot.com/ for complete details �� ��
Sun Pharma gets USFDA approval for generic Razadyne ER
Sun Pharma announced that its subsidiary has received USFDA approval for its ANDA to
market the generic version of Razadyne ER, (galantamine hydrobromide), extended-release
capsules. These extended-release capsules, 8 mg (base), 16 mg (base) and 24 mg (base),
are indicated in the treatment of mild to moderate dementia of the Alzheimer’s type.
Razadyne-ER has annual sales of approximately US $50mn in the US. Razadyne is a
registered trademark of Ortho-McNeil Janssen Pharmaceuticals, Inc.
Considering the market size of the product, the upsides from the same would be limited and
thereby we maintain our estimates and have a Neutral rating on the stock
No comments:
Post a Comment